Jenny Heathcote

Q: What Schools Are Affiliated With Jenny Heathcote

Jenny Heathcote is affiliated with the following schools: University of Calgary, McGill University, University of British Columbia, University of Toronto

Jenny Heathcote's AcademicInfluence.com Rankings

Jenny Heathcote

Philosophy

#10550

World Rank

#14466

Historical Rank

Logic

#7421

World Rank

#9171

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Jenny Heathcote Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Elizabeth Jane "Jenny" Heathcote was a professor of medicine at the University of Toronto and a gastroenterologist and scientist at University Health Network in Toronto specializing in liver disease. She retired in 2013.

(See a Problem?)

Jenny Heathcote's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. (1999) (2667)
Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B (1993) (1043)
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) (1998) (929)
EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. (1999) (715)
Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial (2000) (513)
Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. (1999) (507)
Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. (2005) (504)
CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B® HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study (2004) (330)
Hepatocellular carcinoma (HCC): a global perspective. (2010) (325)
Screening for renal disease using serum creatinine: who are we missing? (2001) (278)
Management of Antiviral Resistance in Patients with Chronic Hepatitis B (2004) (253)
High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. (2001) (245)
The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment‐naïve hepatitis C patients (2009) (240)
Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. (2008) (204)
Diabetes mellitus in the aetiology of Dupuytren's disease. (1984) (199)
High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C (2003) (195)
Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. (2006) (185)
World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. (2010) (182)
The demography of primary biliary cirrhosis in ontario, canada (1990) (181)
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus (2011) (179)
Treatment of hepatitis C (2005) (178)
Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase (2003) (177)
A pilot study of the CY‐1899 T‐cell vaccine in subjects chronically infected with hepatitis B virus (1999) (168)
INCIDENCE AND CLINICAL SIGNIFICANCE OF e ANTIGEN AND ANTIBODY IN ACUTE AND CHRONIC LIVER DISEASE (1975) (159)
A prospective controlled trial of azathioprine in primary biliary cirrhosis. (1976) (144)
No association between hepatitis C and B‐cell lymphoma (1999) (128)
Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study. (2012) (117)
Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. (2004) (113)
ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. (2010) (111)
Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. (2010) (108)
American association for the study of liver diseases endpoints conference: Design and endpoints for clinical trials in primary biliary cirrhosis (2010) (105)
Arthritis, vasculitis, and cryoglobulinemia associated with relapsing hepatitis A virus infection. (1986) (104)
Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin (2001) (98)
Impact of Asian Race on Response to Combination Therapy With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C (2007) (96)
Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. (1999) (92)
Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. (1990) (90)
Hepatitis C–related cirrhosis: A predictor of diabetes after liver transplantation (2000) (84)
Treating chronic hepatitis C with pegylated interferon alfa‐2a (40 KD) and ribavirin in clinical practice (2006) (84)
Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? (1992) (80)
Hepatitis C viral infection in the immunosuppressed patient (1998) (79)
Role of hepatitis-B antigen carriers in non-parenteral transmission of the hepatitis-B virus. (1974) (78)
Spread of acute type-B hepatitis in London. (1973) (74)
HIV-Positive Patients With Nonalcoholic Fatty Liver Disease Have a Lower Body Mass Index and Are More Physically Active Than HIV-Negative Patients (2007) (73)
Chaparral-induced hepatic injury. (1995) (68)
P.102 Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy (2006) (68)
The impact of hepatitis B knowledge and stigma on screening in Canadian Chinese persons. (2012) (67)
Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial (2005) (64)
Health state utilities and quality of life in patients with hepatitis B. (2012) (62)
The clinical expression of primary biliary cirrhosis. (1997) (61)
Sociocultural factors that potentially affect the institution of prevention and treatment strategies for hepatitis B in Chinese Canadians (2009) (60)
Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada between 1986 and 1990 (2004) (57)
Primary Biliary Cirrhosis, Sicca Complex, and Dysphagia (1997) (54)
The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. (2010) (53)
Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole. (1994) (52)
Intrahepatic cholestasis in childhood. (1976) (49)
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies (2013) (49)
Cost‐effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis (1999) (48)
Biliary atresia and survival into adulthood without transplantation: a collaborative multicentre clinic review (2011) (47)
The need to improve fertility awareness (2017) (47)
Determination of hepatitis B phenotype using biochemical and serological markers (2017) (46)
Lamivudine and intron a combination treatment in patients with chronic hepatitis B infection (1998) (46)
The Laennec grading system for assessment of hepatic fibrosis Validation by correlation with wedged hepatic vein pressure and clinical features (2000) (44)
Serum alpha-fetoprotein levels in patients with acute and chronic liver disease. Relation to hepatocellular regeneration and development of primary liver cell carcinoma. (1977) (42)
Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C (1998) (42)
Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma. (1987) (41)
Twenty‐four novel mutations in Wilson disease patients of predominantly European ancestry (2005) (40)
46 Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES) (2004) (39)
Comparative histogenesis and morphogenesis of mucoepidermoid carcinoma and pleomorphic adenoma (1990) (38)
Pancreatic Pseudotumor with Sclerosing Pancreato-Cholangitis: Is This a Systemic Disease? (2004) (38)
A Canadian screening program for hepatitis C: Is now the time? (2013) (37)
1044 TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON- ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY (2009) (37)
Gene Expression Profiling of Acute Liver Stress During Living Donor Liver Transplantation (2006) (37)
Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy (2001) (34)
Chronic persistent hepatitis: hepatitis B virus markers and histological follow-up. (1979) (34)
A 24‐week dietary and physical activity lifestyle intervention reduces hepatic insulin resistance in the obese with chronic hepatitis C (2013) (33)
Antiviral therapy for patients with chronic hepatitis C. (2000) (32)
Three atypical cases of Wilson disease: assessment of the Leipzig scoring system in making a diagnosis. (2007) (32)
Management of hepatitis B. (2011) (31)
Liver Disease in Pregnancy (2004) (31)
988 SUSTAINED VIRAL RESPONSE (SVR) IS DEPENDENT ON BASELINE CHARACTERISTICS IN THE RETREATMENT OF PREVIOUS ALFA INTERFERON/RIBAVIRIN (I/R) NONRESPONDERS (NR): FINAL RESULTS FROM THE EPIC3 PROGRAM (2008) (30)
Variant syndromes of autoimmune hepatitis. (2002) (30)
Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. (2006) (30)
143 EFFICACY AND SAFETY OF INCREASING DOSES OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A IN TREATMENT NAIVE CHRONIC HCV PATIENTS (2008) (29)
Treatment of HBe antigen-positive chronic hepatitis B. (2003) (28)
Hepatitis C and diabetes: one treatment for two diseases? (2010) (28)
DUPUYTREN'S DISEASE AND DIABETES MELLITUS (1981) (26)
Sociocultural factors that potentially affect the institution of prevention and treatment strategies for prevention of hepatitis B in Chinese Canadians. (2009) (24)
Consensus interferon: a novel interferon for the treatment of hepatitis C (1998) (23)
Can Turner syndrome teach us about the pathogenesis of chronic cholestasis? (2004) (22)
Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study) (2005) (22)
Primary biliary cirrhosis: Report of a focus study group (2004) (22)
The professional lives of women in gastroenterology: a Canadian comparison study with men. (1997) (22)
New insights into autoimmune liver diseases (2008) (21)
Polymorphisms of HLA‐DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B (2014) (21)
Does hepatic vein transit time performed with contrast-enhanced ultrasound predict the severity of hepatic fibrosis? (2011) (20)
Weighty issues in hepatitis C (2002) (20)
Interferon‐associated lymphocyte 2′,5′‐oligoadenylate synthetase in acute and chronic viral hepatitis (1989) (20)
4 SVR WITH TELAPREVIR, PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV PATIENTS WITH WELL-CHARACTERIZED PRIOR NULL RESPONSE, PARTIAL RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE AFTER PR (2010) (20)
CpG ODN is safe and highly effective in humans as adjuvant to HBV vaccine Preliminary results of phase I trial with CpG ODN 7909 (2000) (19)
Oral prostaglandin (PGE2) therapy for chronic viral hepatitis B and C (1999) (19)
ISG 15 , a ubiquitin-like interferon-stimulated gene , promotes hepatitis C virus production in vitro : implications for chronic infection and response to treatment (2010) (18)
The distribution of nicotinic acid in wheat and maize (1952) (18)
Primary biliary cirrhosis in a patient with Turner syndrome. (2005) (18)
Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B (2003) (18)
Long term follow-up of patients with chronic hepatitis C treated with interferon alpha. (2000) (16)
Perforation of an adenocarcinoma of the small bowel affected by regional enteritis. (1980) (16)
52 A randomized trial of telbivudine (LDT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysis (2006) (16)
Review: Treatment of primary biliary cirrhosis (1996) (16)
Indications for interferon/ribavirin therapy in hepatitis C patients: findings from a survey of Canadian hepatologists. (2003) (16)
Update on primary biliary cirrhosis. (2000) (15)
M1908 Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Negative Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 102) (2008) (15)
Diffuse skin reaction in patient with hepatitis B, treated with two different formulations of pegylated interferon. (2005) (15)
The use of nuclear magnetic resonance imaging in monitoring total body iron in hemodialysis patients with hemosiderosis treated with erythropoietin and phlebotomy. (1992) (14)
Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients. (2006) (13)
Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis (1998) (13)
MAID : An effect size based model for microarray data integration across laboratories and platforms (2008) (13)
Durability of Serological Remission in Chronic Hepatitis C Treated With Interferon-Alpha-2B (1998) (12)
Immigrant patients with chronic hepatitis C and advanced fibrosis have a higher risk of hepatocellular carcinoma (2012) (12)
Retreatment of chronic hepatitis C: who and how? (2009) (12)
A urinary substance in patients with acute type-B hepatitis and their household contacts. (1973) (12)
493 Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 year (2006) (10)
Phase III Comparison of Telbivudine vs Lamivudine in Patients with Chronic Hepatitis B: Efficacy, Safety, and Predictors of Response at 1 Year (2006) (10)
51 Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients (2006) (9)
The hepatitis B carrier state--a follow-up study of 100 consecutive cases. (1987) (9)
Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions (2006) (9)
Multiple hepatic abscesses: cholangiographic changes simulating sclerosing cholangitis and resolution after percutaneous drainage. (1990) (9)
Treatment Strategies for Autoimmune Hepatitis (2006) (8)
Detection, by three techniques, of hepatitis B surface antigen (HBsAg) and determination of HBsAg and anti-HBs titres in patients with chronic liver disease. (1977) (8)
À La Carte Interferon for Hepatitis C? (2000) (7)
Osteoporosis in chronic liver disease (1999) (7)
[124] 76 WEEK FOLLOW UP OF HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH TELBIVUDINE, ADEFOVIR OR SWITCHED FROM ADEFOVIR TO TELBIVUDINE (2007) (7)
Lamivudine therapy in patients with anti HBe positive chronic hepatitis B; end of treatment analysis (1998) (7)
The laboratory in the diagnosis and management of viral hepatitis. (1974) (7)
Comprar Sherlock's diseases of the liver and biliary system | J. Dooley | 9781405134897 | Wiley (2011) (7)
Pegylated interferon monotherapy for chronic hepatitis C. (2004) (7)
M1913 Lack of Influence of Baseline Genotype On Antiviral Response in Subjects with Chronic Hepatitis B Infection Receiving Tenofovir Df 300 Mg Qd for 1 Year (2008) (6)
The pruritus of cholestasis is relieved by an opiate antagonist: Is this pruritus a centrally mediated phenomenon? (1996) (6)
The role of interferon in the treatment of viral hepatitis. (1994) (6)
Early prediction of nonresponders to treatment with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. (2003) (6)
295 Final Results of the EPIC3 Cirrhosis Maintenance Trial: Pegintron Maintenance Therapy in Cirrhotic (METAVIR F4) HCV Patients, Who Failed to Respond to Interferon/Ribavirn (IR) Therapy: (2009) (6)
689 LACK OF INFLUENCE OF BASELINE GENOTYPE ON ANTIVIRAL RESPONSE IN SUBJECTS WITH CHRONIC HEPATITIS B INFECTION RECEIVING TENOFOVIR DF 300 MG QD FOR 1 YEAR (2008) (6)
755 SUSTAINED VIROLOGICAL RESPONSE AFTER 4-WEEK TREATMENT WITH DEBIO 025 MONOTHERAPY OR COADMINISTERED WITH PEG-IFNα2A IN HCV GENOTYPE 1 AND 3 PATIENTS (2010) (5)
W1806 Two Years Safety and Efficacy of Tenofovir Disoproxil Fumarate (TDF) in Patients with HBV-Induced Cirrhosis (2009) (5)
Acute hepatitis in Crigler-Najjar syndrome. (1987) (5)
Sulindac hepatotoxicity (1982) (5)
[513] EFFICACY OF TELBIVUDINE VS LAMIVUDINE AT 2 YEARS IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B WHO ARE ELIGIBLE FOR TREATMENT BASED ON GUIDELINES (2007) (5)
Dangers of immunosuppressive therapy in hepatitis B virus carriers. (1992) (5)
Hepatotoxicity: newer aspects of pathogenesis and treatment. (1995) (4)
Correlation of health-related quality of life with virological response and early treatment discontinuation in patients treated with pegylated (40 kDa) interferon alfa-2a (PEGASYS) compared with standard inferferon alfa-2a (2001) (4)
Proceedings: Serum alphafetoprotein levels in liver disease: relation to hepatocellular regeneration and development of hepatoma. (1975) (4)
Pharmacokinetic disposition of isoxicam in hepatic cirrhosis. (1987) (4)
The epidemiological importance of `ay' and `ad' subtypes of the HB-Ag (1974) (4)
1017 EFFICACY OF TENOFOVIR DF TREATMENT IN PATIENTS WITH A SUBOPTIMAL RESPONSE TO ADEFOVIR DIPIVOXIL (2010) (3)
Durability of hbeag seroconversion in chronic hepatitis B patients after lamivudine A-interferon or lamivudine A- interferon combination therapy (2001) (3)
W1056 Adequacy of Liver Biopsies: Variability Across Different Methods of Specimen Acquisition (2008) (2)
New diagnostic tests and their implications in primary biliary cirrhosis and primary sclerosing cholangitis (1995) (2)
Unusual Infections Complicating the Use of Steroids with Severe Alcoholic Hepatitis: Report of 2 Cases (1995) (2)
831 FibroTest (Ft) Baseline Value Is An Independent Predictor of Early (EVR) and Sustained Virological Response (SVR) in Non-Responders Patients Re-Treated with Pegylated Interferon Alfa-2B (PEG-2B) and Ribavirin in EPIC3 (2009) (2)
Cholestasis induced by Chinese herbal remedy Xia‐Ku‐Hua‐Tan‐Pian (2011) (2)
Personal reminiscences: Sheila Sherlock (2002) (2)
Treatment of primary biliary cirrhosis. (1996) (2)
World gastroenterology organisation practice guideline - hepatitis B September 2008 (2009) (2)
822 PLATELET COUNT PREDICTS SUSTAINED VIRAL RESPONSE (SVR) IN THE RE-TREATMENT OF PREVIOUS INTERFERON/RIBAVIRIN NON-RESPONDERS (NR): RESULTS FROM THE EPIC3 PROGRAM (2008) (2)
S1000 Results from the Epic3 Program: Platelet Counts Are Strong Predictors of Sustained Viral Response (SVR) in the RE-Treatment of Previous Interferon/Ribavirin Non-Responders (Nr) (2008) (2)
Primary biliary cirrhosis with features of autoimmune hepatitis (2001) (2)
M1771 The Prevalence of Insulin Resistance in Patients with Chronic Hepatitis C and B (2008) (1)
T regulatory cells and autoimmune liver disease (2008) (1)
Task force on training in hepatology (1996) (1)
Characteristics of HBeAg-positive patients chronically infectedwith hepatitis b virus (HBV) who achieved hbsag loss/seroconversion following tenofovir disoproxil fumarate (TDF) treatment (2009) (1)
S1786 IgG4-Associated Autoimmune Cholangiopathy (AIC): A Steroid-Responsive Multi-System Disease (2009) (1)
Do we know how to achieve optimal response to Pegylated interferon alpha and Ribavirin (2003) (1)
Proceedings: Serological findings amongst domestic contacts of persons with transient and persistent hepatitis B antigenaemia. (1974) (1)
PL-001 USP18 stimulates HCV production and blunts the antiviral effect of IFNα independent of its protease activity (2010) (1)
Overlap syndromes and changing diagnoses (2000) (1)
The Diploma of the Faculty of Sexual and Reproductive Healthcare: an innovative new training programme (2010) (1)
Morbid Obesity and HCV: Management Strategies (2010) (1)
Tenofovir in the treatment of chronic hepatitis B (2011) (1)
The significance of AST changes in patients with rheumatoid arthritis treated with methotrexate. (1996) (1)
Analysis of immune response in non-responders to hepatitis B virus vaccination or infection (1993) (1)
Gene expression profiling of hepatocellular cancer identifies a consistent pattern in cancerous and distant liver tissue: Arguments for a field defect (2005) (1)
Wright's Liver and Biliary Disease: Pathophysiology, diagnosis and management. 3rd ed: By G. H. Millward-Sadler, R. Wright, and M. J. P. Arthur. 1668 pp. W. B. Saunders, Philadelphia, Pennsylvania, 1992. ISBN 0-7020-1392-7 (1993) (1)
Theepidemiological importance of'ay' and'ad' subtypes oftheHB-Ag (1974) (1)
Wright's Liver and Biliary Disease: Pathophysiology, diagnosis and management. 3rd ed (1993) (1)
CA3 A COST-EFFECTIVENESS ANALYSIS OF HEPATITIS C SCREENING AMONG IMMIGRANTS IN CANADA (2008) (1)
Diagnosis of primary biliary liver diseases, overlap syndromes and changing diagnoses (2005) (1)
Altered Cyclosporine Absorption in a Patient with Ulcerative Colitis, Sclerosing Cholangitis and Pancreatic Insufficiency (1991) (0)
Correction: Hepatitis Nomenclature (1993) (0)
O.045 Chronic hepatitis B: When to institute treatment (2006) (0)
When to treat patients with chronic hepatitis C (2004) (0)
Perforation ofanadenocarcinoma ofthesmall bowel affected byregional enteritis (1980) (0)
PP-141 Predicting treatment response in hepatitis C virus infected patients: from gene to protein expression (2009) (0)
Points: Dupuytren's disease (1985) (0)
Long-term safety beyond 48 weeks of adefovir dipivoxil (ADV) 10 Mg once daily for chronic hepatitis B (CHB): An integrated analysis of two phase III studies (2003) (0)
What's New and Controversial? A Critical Critique - The Liver (1990) (0)
939 Predicting liver disease severity in E antigen negative chronic hepatitis B (2003) (0)
The Blood Doctor (2011) (0)
146 The Impact of Cirrhosis or Prior Liver Transplant On Obstetrical Outcomes: A National Study (2009) (0)
Safety and efficacy in lamivudine experienced chronic hepatitis B (CHB) patients treated for two years with tenofovir disoproxil fumarate (2009) (0)
Hepatitis C: ribavirin and/or interferon? (1996) (0)
Workshop/poster session 9: Cytokines in the development of innate and adaptive immunity (2008) (0)
, infection : a randomised trial treatment of patients with chronic hepatitis B Lamivudine and alpha interferon combination (2000) (0)
Screening and cloning of gene of hepatocyte protein interacting with HCV NS 5 ATP 4 A protein (2009) (0)
T1013 Association Between BMI and Hepatitis C in the United States (2008) (0)
M1782 Characteristics of HBeAg-Positive Patients with HBsAg Loss/Seroconversion Following Treatment with Tenofovir Disoproxil Fumarate (TDF) (2009) (0)
EDUCATION PRACTICE Management of Hepatitis B (2011) (0)
Chapter 12 Primary Biliary Cirrhosis (2008) (0)
P66 SVR with telaprevir, peginterferon alfa-2A and ribavirin in HCV patients with well-characterised prior null response, partial response, viral breakthrough or relapse after peginterferon+ ribavirin (2010) (0)
Clinical trials in chronic liver disease - what do they achieve? (2004) (0)
339 DIFFERENTIAL ACCUMULATION OF CIRCULATING BILE ACID GLUCURONIDES IN PATIENTS WITH MODERATE AND SEVERE CHOLESTASIS: A TARGETED METABOLOMIC STUDY (2012) (0)
iagnosis and Management of Cholestatic Liver Disease (2007) (0)
769 USP18 STIMULATES HCV PRODUCTION: UPREGULATION OF THE SURFACE ENTRY RECEPTOR CD81 IN VITRO (2011) (0)
Primary Biliary Cholangitisa (2017) (0)
Water Quality in Western Rice County: A Study of Caron, Cedar, French, Hunt, Mazaska, Rice, Roberds, and Shields Lakes (2004) (0)
715 BASELINE GENOTYPE AND HBSAG WERE FOUND TO HAVE SIGNIFICANT ASSOCIATION WITH HBEAG SEROCONVERSION FOLLOWING UP TO 4 YEARS OF TENOFOVIR DISOPROXIL FUMARATE TREATMENT (2011) (0)
Federally funded research in hepatology (2004) (0)
Session 8: Providing Scientific Evidence: RCTs and Beyond (2007) (0)
DNA ploidy in hepatocellular carcinoma (1992) (0)
321 Safety and Efficacy of 96 Weeks of Tenofovir Disoproxil Fumarate Therapy in Lamivudine Experienced Patients (2009) (0)
Primary Biliary Cirrhosis: Challenges for the Future. (2006) (0)
Consensus + pegylated interferon (2003) (0)
413 FIBROTEST (FT) VALUE INDEPENDENTLY PREDICTS EARLY (EVR) AND SUSTAINED VIROLOGICAL RESPONSE (SVR) IN NON-RESPONDER PATIENTS RE-TREATED WITH PEGYLATED INTERFERON ALFA-2B (PEG-2B) AND RIBAVIRIN IN EPIC3 (2009) (0)
New Insights in Autoimmune Liver Disease (2008) (0)
Autoimmune cholangitis Autoimmune cholangitis (0)
Two year safety and tolerability of tenofovir disoproxil fumarate (TDF) treatment in HBeAg negative and HBEAG positive patients with chronic hepatitis B (CHB) (2009) (0)
PIN43 NATURAL HISTORY OF CHRONIC HCV INFECTION OBTAINED THROUGH INJECTION DRUG USE: A BAYESIAN META-ANALYSIS (2008) (0)
931 BAYESIAN MIXED TREATMENT COMPARISON META- ANALYSIS OF OUTCOMES OF TREATMENT FOR CHRONIC HEPATITIS B IN HBeAg-POSITIVE PATIENTS (2009) (0)
W1814 Safety and Tolerability of 96 Weeks of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg Negative and Positive Patients Infected with Chronic Hepatitis B (CHB) (2009) (0)
PL-001 ISG15, an ubiquitin-like interferon stimulated gene, promotes HCV production in vitro (2009) (0)
Therapies for PBC (1992) (0)
Proceedings: The progress of children with intrahepatic cholestasis. (1974) (0)
Treatment of Chronic Hepatitis C (2007) (0)
5 Steatosis in Chronic Hepatitis C: Changes in Hepatic Fatty Acid Composition (2008) (0)
Results of lamivudine therapy for HBe antigen positive hepatitis (in the West). (2003) (0)
T1038 A Needs Assessment Among Primary Healthcare Providers: Management of Chronic Hepatitis B (2009) (0)
265 Early but not late interferon alpha therapy against hepatitis C rescues polyfunctional CD4+ and CD8+ memory T cells (2008) (0)
Book Review Liver Immunology: Principles and Practice Edited by M. Eric Gershwin, John M. Vierling, and Michael P. Manns. 486 pp., illustrated. Totowa, NJ, Humana Press, 2007. $169. 978-1-58829-818-8 (2008) (0)
1147 5-year follow-up of 998 chronic hepatitis B patients to determine long-term safety of lamivudine and clinical consequences of lamivudine-resistant mutations (2003) (0)
W1799 Preemptive Adefovir Dipivoxil in Chronic Hepatitis B Patients Undergoing Chemotherapy Is Associated with Fewer Hepatitis B Virological Resistance Mutations Compared with the Use of Lamivudine (2009) (0)
Immune-mediated liver disease (2011) (0)
Chapter 28. Primary Biliary Cirrhosis (2007) (0)
Appendix 7: Screening for hepatitis C infection: evidence review f or newly arriving immigrants and refugees (2011) (0)

This paper list is powered by the following services:

Other Resources About Jenny Heathcote

en.wikipedia.org

What Schools Are Affiliated With Jenny Heathcote?

Jenny Heathcote is affiliated with the following schools: